You are here: Home » News/Headlines »

EMA goes one step forward about biosimilars

October 4, 2011 11:13 AM

Share this Article

Tags:

ema logo EMA goes one step forward about biosimilars

European Medicines Agency (EMA) goes one step forward about biosimilars and invites feedback on plans to revise existing guidelines on biosimilar medicines.

As well known, Europe has the most regulated biosimilars market in the world. Europe’s regulatory watchdog, EMA (formerly EMEA) has published guidelines and approved several biosimilars till today. Additionally, EMA has also completed their preparations about biosimilar monoclonal antibodies guideline which will soon be published.

Now, the European Medicines Agency published a concept paper to start the three-month consultation period about the revision of the guideline of biosimilars. The deadline for comments is the last day of 2011 and the revised guideline will be published during the year 2012.

If you want to have look at the concept paper which asks for advice about clinical and non-clinical issues, you can click the link below:

Concept paper on the revision of the guideline on similar biological medicinal products

No related posts.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


 

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.
We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!

Latest Posts on Biosimilar News

  • Events Upcoming Events World Drug Repositioning Congress Europe

    World Drug Repositioning Congress Europe

    Terrapinn is organizing the World Drug Repositioning Congress – Europe in London, UK on 11-13 September 2012. The event is co-located with the World Biosimilar Congress in Jumeirah Carlton Tower Hotel in London. The 2012 World Drug Repositioning Congress is Europe’s first commercially orientated conference that provides key technical and strategic solutions to challenges faced when adopting drug repositioning into your R&D efforts. The World Drug Repositioning Congress Europe is where decision-makers from the wider biopharmaceutical industry and service providers meet to determine best practice [...]

    Read more →
  • Events Featured Upcoming Events World Biosimilar Congress Europe

    World Biosimilar Congress Europe

    Terrapinn is organizing the World Biosimilar Congress – Europe in London, UK on 11-13 September 2012. The event is co-located with the World Drug Repositioning Congress in Jumeirah Carlton Tower Hotel in London. If you attend this event, you will be able to get competitive insight into global regulatory strategies, and find out how to successfully bring biosimilars to-market in developed and developing regions. Leading companies from India, Israel, Switzerland, UK, USA, Germany and more will be speaking at the World Biosimilars Congress in [...]

    Read more →
  • Events Upcoming Events Regulatory Strategies – The Pathway Forward in the EU, US and the Rest of the World

    Regulatory Strategies – The Pathway Forward in the EU, US and the Rest of the World

    Speid & Associates, Inc. is organizing the third WEBEX in a series of WEBEX’s focused on the strategic development of biosimilars.   This third presentation will be given by Dr. Lorna Speid and the event will be on 5th of June and will be held from 7:30 am PDT (10:30 am EST) to 9:00 am PDT (12:00 pm EST). WEBEX considers the importance of developing sophisticated regulatory strategies for the development of biosimilars. Space is limited and companies actively involved in [...]

    Read more →
  • News/Headlines Meaningful finger-print-like analysis of biologics by Array Bridge

    Meaningful finger-print-like analysis of biologics by Array Bridge

    Array Bridge Inc. has developed a Protein Conformation Array (PCA) kit for three dimensional structural comparability analysis of Biologics and Biosimilars. These PCA kits can provide valuable information on the 3-D structure and heterogeneity of biologics and can be used at many stages of biologics/biosimilars development including cell line selection, process development, formulation development and product release testing. The kit is easy to use and in an ELISA format, and with a series of antibodies to overlapping peptides, spanning the [...]

    Read more →
  • Events Upcoming Events Life Science Legal & Business Strategy Conference

    Life Science Legal & Business Strategy Conference

    Global Technology Community is organizing the Life Science Legal & Business Strategy Conference in San Diego, California on June 7-8, 2012. The event provides executive level insight into the legal issues of greatest concern in today’s business environment. Respected litigators, counselors, advisors and industry professionals offer in depth knowledge and perspectives into the latest regulatory changes and how to develop plans to protect your organization and its products as well as exploit opportunities that may only exist for a limited [...]

    Read more →
  • News/Headlines Policies GPhA underscores commitment to providing consumers timely access to safe and effective biosimilars

    GPhA underscores commitment to providing consumers timely access to safe and effective biosimilars

    The Generic Pharmaceutical Association (GPhA) last week reiterated its commitment to safeguarding the intent of the Biologics Price Competition and Innovation Act (BPCIA) and ensuring that patients have timely access to safe, effective and affordable biosimilar medications. “GPhA’s priority is to support safe, pure and potent biologics being made available to all patients who need them with no compromise in quality,” said Ahaviah Glaser, GPhA Vice President for Policy and Strategic Alliances, in comments to the FDA public meeting. “Moving [...]

    Read more →
  • Events Upcoming Events Emerging trends in biopharmaceutical manufacturing webinar

    Emerging trends in biopharmaceutical manufacturing webinar

    Report Linker is organizing a free webinar about the Emerging Trends in Biopharmaceutical Manufacturing.  The 30-minute webinar will be on May 22 at 12 pm EST and be presented by senior expert Eric S. Langer from BioPlan Associates and ReportLinker. During this live session, you will learn about: Recent biopharmaceutical spending, investment and outsourcing trends Top 11 new vendor technologies Manufacturing in developing countries Single-use equipment, biosimilars, bioprocessing and more. The website of the conference is: Report Linker Webinar Would you like to post an event [...]

    Read more →
  • News/Headlines Alliance for Safe Biologic Medicines urge FDA to ensure that patient safety is the cornerstone of biosimilar pathway

    Alliance for Safe Biologic Medicines urge FDA to ensure that patient safety is the cornerstone of biosimilar pathway

    Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines outlined five areas of concern that the U.S. FDA should resolve before they allow biosimilar medications on the U.S. drug market in prepared testimony for the FDA’s May 11th public hearing.   “We applaud the FDA’s efforts to bring biosimilars to the U.S. market, but would urge a deliberate approach that is becoming of FDA’s critical role of ensuring the safety and efficacy of the nation’s drug supply,” Dr. Dolinar said.  “The [...]

    Read more →